Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Notice of General Meeting
April 17, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 2 May 2025 at 13:00 BST was posted to shareholders yesterday. The Board of Directors is proposing three resolutions: Ordinary Resolutions1.» Mehr auf globenewswire.com
Preliminary Results for the Year Ended 31 December 2024
April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces its audited preliminary results for the year ended 31 December 2024. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs.» Mehr auf globenewswire.com
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).» Mehr auf accessnewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | −2,58 Mio | - |
Nettoeinkommen | −3,90 Mio | - |
EBITDA | −4,90 Mio | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 2,05k€ |
Anzahl Aktien | 1,67k |
52 Wochen-Hoch/Tief | 64,90€ - 1,00€ |
Dividenden | Nein |
Beta | 1,71 |
KGV (PE Ratio) | 0,00 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,00 |
KUV (PS Ratio) | 0,02 |
Unternehmensprofil
Name | BIODEXA PHARMA ADR O.N. Aktie |
CEO | Stephen Anthony Stamp |
Mitarbeiter | 13 |
Assets entdecken
Shareholder von BIODEXA PHARMA ADR O.N. Aktie investieren auch in folgende Assets